337 related articles for article (PubMed ID: 30444747)
61. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
62. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.
Su MG; Potts LB; Tsai JH
Am J Ophthalmol Case Rep; 2020 Sep; 19():100755. PubMed ID: 32490287
[TBL] [Abstract][Full Text] [Related]
63. Palliative Use of Vismodegib.
Lam C; Larson E; Vidimos AT; Billingsley EM
Dermatol Surg; 2020 Feb; 46(2):272-276. PubMed ID: 30789523
[No Abstract] [Full Text] [Related]
64. Neoadjuvant Vismodegib Before Mohs: Lack of Tissue Sparing and Squamous Differentiation of Basal Cell Carcinoma in a Patient With Chronic Lymphocytic Leukemia.
Guo D; Kossintseva I; Leitenberger J
Dermatol Surg; 2016 Jun; 42(6):780-3. PubMed ID: 27153042
[No Abstract] [Full Text] [Related]
65. Clinical factors influencing periocular surgical defects after Mohs micrographic surgery.
Carter KD; Nerad JA; Whitaker DC
Ophthalmic Plast Reconstr Surg; 1999 Mar; 15(2):83-91. PubMed ID: 10189634
[TBL] [Abstract][Full Text] [Related]
66. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
Nayyar PM; Chang ALS; Sarin K; Ratner D
Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
[No Abstract] [Full Text] [Related]
67. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data.
Lawrence CM; Haniffa M; Dahl MG
Br J Dermatol; 2009 Mar; 160(3):573-80. PubMed ID: 19210500
[TBL] [Abstract][Full Text] [Related]
68. Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.
Wong KY; Fife K; Lear JT; Price RD; Durrani AJ
Plast Reconstr Surg Glob Open; 2017 Jul; 5(7):e1424. PubMed ID: 28831360
[TBL] [Abstract][Full Text] [Related]
69. Basal cell carcinoma of the periocular region.
Arlette JP; Carruthers A; Threlfall WJ; Warshawski LM
J Cutan Med Surg; 1998 Apr; 2(4):205-8. PubMed ID: 9558303
[TBL] [Abstract][Full Text] [Related]
70. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
71. Periocular microcystic adnexal carcinoma: management and outcome with Mohs' micrographic surgery.
Leibovitch I; Huilgol SC; Richards S; Paver R; Selva D
Ophthalmologica; 2006; 220(2):109-13. PubMed ID: 16491033
[TBL] [Abstract][Full Text] [Related]
72. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up.
Malhotra R; Huilgol SC; Huynh NT; Selva D
Ophthalmology; 2004 Apr; 111(4):631-6. PubMed ID: 15051193
[TBL] [Abstract][Full Text] [Related]
73. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
74. Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure.
Morris DS; Elzaridi E; Clarke L; Dickinson AJ; Lawrence CM
Br J Ophthalmol; 2009 Apr; 93(4):474-6. PubMed ID: 19060015
[TBL] [Abstract][Full Text] [Related]
75. The efficacy of curettage in delineating margins of basal cell carcinoma before Mohs micrographic surgery.
Ratner D; Bagiella E
Dermatol Surg; 2003 Sep; 29(9):899-903. PubMed ID: 12930329
[TBL] [Abstract][Full Text] [Related]
76. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
[No Abstract] [Full Text] [Related]
77. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
78. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.
Marescassier H; Dousset L; Beylot-Barry M; Célérier P; Vaillant L; Bedane C; Leclère F; Wierzbicka-Hainaut E; Masson Regnault M
Dermatology; 2021; 237(6):1023-1028. PubMed ID: 33472195
[TBL] [Abstract][Full Text] [Related]
79. Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology.
França K; Alqubaisy Y; Hassanein A; Nouri K; Lotti T
Wien Med Wochenschr; 2018 Jun; 168(9-10):218-227. PubMed ID: 27832425
[TBL] [Abstract][Full Text] [Related]
80. Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study.
Sin CW; Barua A; Cook A
Int J Dermatol; 2016 Sep; 55(9):1044-7. PubMed ID: 27152747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
